This HTML5 document contains 138 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n21http://linked.opendata.cz/resource/drugbank/drug/DB00213/identifier/kegg-compound/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00213/identifier/bindingdb/
n32http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00213/identifier/pubchem-compound/
dctermshttp://purl.org/dc/terms/
n26http://linked.opendata.cz/resource/AHFS/
n9http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/mesh/concept/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00213/identifier/kegg-drug/
n27http://linked.opendata.cz/resource/drugbank/dosage/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00213/identifier/pubchem-substance/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00213/identifier/drugbank/
n29http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB00213/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/patent/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00213/identifier/chemspider/
n4http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/medicinal-product/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00213/identifier/chebi/
n5http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n31http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00213/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00213/identifier/wikipedia/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00213
rdf:type
n5:Drug
n5:description
Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.
n5:dosage
n27:271B5D3B-363D-11E5-9242-09173F13E4C5 n27:271B5D3C-363D-11E5-9242-09173F13E4C5 n27:271B5D3D-363D-11E5-9242-09173F13E4C5 n27:271B5D3E-363D-11E5-9242-09173F13E4C5 n27:271B5D36-363D-11E5-9242-09173F13E4C5 n27:271B5D37-363D-11E5-9242-09173F13E4C5 n27:271B5D38-363D-11E5-9242-09173F13E4C5 n27:271B5D39-363D-11E5-9242-09173F13E4C5 n27:271B5D3A-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
1 hour
n5:indication
Short-term (up to 16 weeks) treatment of erosive esophagitis.
n5:manufacturer
n9:271B5D20-363D-11E5-9242-09173F13E4C5 n9:271B5D21-363D-11E5-9242-09173F13E4C5 n9:271B5D1E-363D-11E5-9242-09173F13E4C5 n9:271B5D1F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n4:DB00213 n29:DB00213
dcterms:title
Pantoprazole
adms:identifier
n12:Pantoprazole n16:46504622 n17:PA450774 n18:4679 n19:D05353 n20:0008-0923-51 n21:C11806 n22:4517 n23:DB00213 n24:50241342 n25:7915
n5:mechanismOfAction
Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by forming a covalent bond to two sites of the (H<sup>+</sup>,K<sup>+</sup> )- ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect is dose- related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.
n5:packager
n9:271B5CFE-363D-11E5-9242-09173F13E4C5 n9:271B5CFF-363D-11E5-9242-09173F13E4C5 n9:271B5D02-363D-11E5-9242-09173F13E4C5 n9:271B5D03-363D-11E5-9242-09173F13E4C5 n9:271B5D00-363D-11E5-9242-09173F13E4C5 n9:271B5D01-363D-11E5-9242-09173F13E4C5 n9:271B5D06-363D-11E5-9242-09173F13E4C5 n9:271B5D07-363D-11E5-9242-09173F13E4C5 n9:271B5D04-363D-11E5-9242-09173F13E4C5 n9:271B5D05-363D-11E5-9242-09173F13E4C5 n9:271B5D0A-363D-11E5-9242-09173F13E4C5 n9:271B5D0B-363D-11E5-9242-09173F13E4C5 n9:271B5D08-363D-11E5-9242-09173F13E4C5 n9:271B5D09-363D-11E5-9242-09173F13E4C5 n9:271B5D0E-363D-11E5-9242-09173F13E4C5 n9:271B5D0F-363D-11E5-9242-09173F13E4C5 n9:271B5D0C-363D-11E5-9242-09173F13E4C5 n9:271B5D0D-363D-11E5-9242-09173F13E4C5 n9:271B5D12-363D-11E5-9242-09173F13E4C5 n9:271B5D13-363D-11E5-9242-09173F13E4C5 n9:271B5D10-363D-11E5-9242-09173F13E4C5 n9:271B5D11-363D-11E5-9242-09173F13E4C5 n9:271B5D16-363D-11E5-9242-09173F13E4C5 n9:271B5D17-363D-11E5-9242-09173F13E4C5 n9:271B5D14-363D-11E5-9242-09173F13E4C5 n9:271B5D15-363D-11E5-9242-09173F13E4C5 n9:271B5D1A-363D-11E5-9242-09173F13E4C5 n9:271B5D1B-363D-11E5-9242-09173F13E4C5 n9:271B5D18-363D-11E5-9242-09173F13E4C5 n9:271B5D19-363D-11E5-9242-09173F13E4C5 n9:271B5D1C-363D-11E5-9242-09173F13E4C5 n9:271B5D1D-363D-11E5-9242-09173F13E4C5
n5:patent
n10:2428870 n10:7544370 n10:4758579 n10:2092694 n10:2341031
n5:routeOfElimination
After administration of a single intravenous dose of 14C-labeled pantoprazole to healthy, normal metabolizer subjects, approximately 71% of the dose was excreted in the urine with 18% excreted in the feces through biliary excretion.
n5:synonym
Pantoprazol Pantoprazolum
n5:toxicity
Single intravenous doses of pantoprazole at 378, 230, and 266 mg/kg (38, 46, and 177 times the recommended human dose based on body surface area) were lethal to mice, rats and dogs, respectively. The symptoms of toxicity included hypoactivity, ataxia, hunched sitting, limb-splay, lateral position, segregation, absence of ear reflex, and tremor. There is limited experience regarding cases of human overdosage, and treatment should be symptomatic and supportive.
n5:volumeOfDistribution
* 11.0 to 23.6 L
n13:hasAHFSCode
n26:56-28-36
n5:foodInteraction
Take without regard to meals.
n5:proteinBinding
98%
n5:salt
n5:synthesisReference
Rudolf Linder, "Freeze-dried pantoprazole preparation and pantoprazole injection." U.S. Patent US20030003058, issued January 02, 2003.
n7:hasConcept
n8:M0177102
foaf:page
n31:pantoprazole.html n32:protonix.htm
n5:IUPAC-Name
n6:271B5D43-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5D49-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5D48-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5D45-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5D46-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5D47-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5D41-363D-11E5-9242-09173F13E4C5 n6:271B5D59-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5D3F-363D-11E5-9242-09173F13E4C5 n6:271B5D42-363D-11E5-9242-09173F13E4C5 n6:271B5D5B-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5D40-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:A02BC02
n5:H-Bond-Acceptor-Count
n6:271B5D4F-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5D50-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5D4A-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5D4B-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5D4D-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5D4C-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5D4E-363D-11E5-9242-09173F13E4C5
n5:absorption
Pantoprazole is well absorbed. It undergoes little first-pass metabolism resulting in an absolute bioavailability of approximately 77%.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
102625-70-7
n5:category
n5:clearance
* 7.6-14.0 L/h
n5:containedIn
n28:271B5D23-363D-11E5-9242-09173F13E4C5 n28:271B5D24-363D-11E5-9242-09173F13E4C5 n28:271B5D22-363D-11E5-9242-09173F13E4C5 n28:271B5D27-363D-11E5-9242-09173F13E4C5 n28:271B5D28-363D-11E5-9242-09173F13E4C5 n28:271B5D25-363D-11E5-9242-09173F13E4C5 n28:271B5D26-363D-11E5-9242-09173F13E4C5 n28:271B5D2B-363D-11E5-9242-09173F13E4C5 n28:271B5D2C-363D-11E5-9242-09173F13E4C5 n28:271B5D29-363D-11E5-9242-09173F13E4C5 n28:271B5D2A-363D-11E5-9242-09173F13E4C5 n28:271B5D2F-363D-11E5-9242-09173F13E4C5 n28:271B5D30-363D-11E5-9242-09173F13E4C5 n28:271B5D2D-363D-11E5-9242-09173F13E4C5 n28:271B5D2E-363D-11E5-9242-09173F13E4C5 n28:271B5D33-363D-11E5-9242-09173F13E4C5 n28:271B5D34-363D-11E5-9242-09173F13E4C5 n28:271B5D31-363D-11E5-9242-09173F13E4C5 n28:271B5D32-363D-11E5-9242-09173F13E4C5 n28:271B5D35-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B5D55-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5D57-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5D58-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B5D5A-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5D54-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5D53-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5D56-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5D44-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5D51-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5D52-363D-11E5-9242-09173F13E4C5